FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]FDAFDA PCAC reviews BPC-157, KPV, TB-500, MOTS-c (Jul 23) and DSIP, Semax, Epitalon (Jul 24, 2026) for 503A compounding eligibilityUPDATESemaglutide and tirzepatide compounding ended — shortage resolved Feb/May 2025REGULATORY12 peptides removed from FDA Category 2 (Apr 23, 2026) — removal is not approval; all remain pending PCAC reviewREGULATORYNo formal FDA reclassification published — no restricted peptide is legal to compound; 5 more peptides go to PCAC before Feb 2027RESEARCHA Real-world Study of Treatment Retention and Adherence to Secukinumab in Patients With Plaque Psoriasis (PsO) With or Without Glucagon-like Peptide-1 Receptor Agonist (GLP-1 RA) Co-therapy [NCT07881783]RESEARCHStudy to Evaluate the Dose-Dependent Effect of Tirzepatide on Gastric Emptying in Adult Patients With Type 1 Diabetes [NCT07951658]RESEARCHA Study of Investigational Tirzepatide (LY3298176) Doses in Participants With Type 2 Diabetes and Obesity [NCT06037252]RESEARCHA Study to Learn About the Study Medicine Called Rimegepant in Adults When Used for the Prevention of Chronic Migraine [NCT07729462]RESEARCHHypersensitivity to Amylin in Post-Traumatic Headache [NCT07340775]RESEARCHEffects of Tirzepatide on Corneal Nerve Morphology and Other Ocular Parameters in Adults With Obesity [NCT07950371]NEWSSTAT+: Peptide market poised to explode with new Hims and Noom launchesRESEARCHAlleviating Carbohydrate Counting for Patients With Type-1 Diabetes Using a Closed Loop System With Weekly Subcutaneous Semaglutide [NCT06387199]RESEARCHWeight Trajectories and Predictive Factors After Semaglutide in Patients With Grade 3 and Complicated Obesity [NCT07423481]RESEARCHSEMAFORCRANIO : Multicenter, Double-blind, Parallel, Randomized Controlled Trial of the Efficacy of Semaglutide in Hypothalamic Obesity Secondary to Craniopharyngioma in Children Aged 12 to 17 Years [NCT07845994]

연구 용도로만 사용. 전체 공지 →

스택 라이브러리

Triple GH Stack

GH Optimizationadvanced

88

상호작용

88
Share
펩타이드

3

일 평균 mcg

957

수준

advanced

추가됨

May 17, 2026

개요

The Triple GH Stack amplifies the classic CJC-1295 + Ipamorelin protocol with Sermorelin, adding a third GHRH-pathway stimulant to maximize pituitary priming and increase the duration of GH stimulation beyond what CJC-1295 alone provides. Sermorelin is the shortest functional GHRH analog — a 29-amino acid truncated version of native GHRH. Where CJC-1295 provides a longer-acting GHRH signal, Sermorelin provides a more physiologically rapid, native-pattern pulse. Together they create a layered stimulation pattern: Sermorelin fires first with a sharp, natural signal, while CJC-1295 extends and sustains the pituitary response over a longer window. Ipamorelin continues to provide ghrelin-pathway amplification, ensuring the pituitary primed by CJC-1295 and Sermorelin releases its maximum GH payload with each pulse. The result is higher peak GH secretion and more frequent physiological pulses throughout the day and night. The 5-days-on/2-days-off cycling on Sermorelin (typically weekdays, off weekends) preserves receptor sensitivity on the GHRH pathway and prevents the tachyphylaxis that can occur with continuous stimulation. This stack is used by advanced practitioners seeking maximum GH axis stimulation without exogenous HGH. Blood work monitoring (IGF-1, fasting glucose) every 6–8 weeks is essential.

용량 프로토콜

CJC-1295

Every day· subcutaneous

CJC-1295에 대한 자세한 내용 →

300 mcg

1회 용량당

Ipamorelin

Every day· subcutaneous

Ipamorelin에 대한 자세한 내용 →

300 mcg

1회 용량당

Sermorelin

5 days on/2 off· subcutaneous

Sermorelin에 대한 자세한 내용 →

500 mcg

1회 용량당

목표 및 증거

Maximum GH outputAnti-agingBody compositionLean muscleRecovery
증거 등급:인체 데이터

경고

  • Multi-GHRH stacking increases risk of pituitary receptor downregulation. Cycle carefully and monitor IGF-1 levels.

Comments

Sign in to join the discussion

주의: 이 스택은 커뮤니티에서 제출된 것이며 연구용으로만 사용됩니다. Peptide Contacts는 제출된 스택의 안전성이나 효능을 검증하지 않습니다. 펩타이드 프로토콜을 사용하기 전에 항상 자격이 있는 의료 전문가와 상의하세요.